Risk factors for avascular necrosis in patients with systemic lupus erythematosus: a multi-center cohort study of Chinese SLE Treatment and Research Group (CSTAR) Registry XXII
Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as os...
Saved in:
Published in | Arthritis research & therapy Vol. 25; no. 1; pp. 78 - 10 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
12.05.2023
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients.
SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model.
One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age ≤ 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI ≥ 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn.
Patients with SLE onset age ≤ 30, arthritis, existing organ damage (SDI ≥ 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention. |
---|---|
AbstractList | Background Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients. Methods SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model. Results One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age [less than or equai to] 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI [greater than or equal to] 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn. Conclusion Patients with SLE onset age [less than or equai to] 30, arthritis, existing organ damage (SDI [greater than or equal to] 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention. Keywords: Systemic lupus erythematosus, Avascular necrosis, Risk factors, Risk stratification Abstract Background Avascular necrosis is a common organ damage in SLE patients, which can influence patients’ life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients. Methods SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model. Results One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age ≤ 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI ≥ 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3–6) and low risk (0–2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn. Conclusion Patients with SLE onset age ≤ 30, arthritis, existing organ damage (SDI ≥ 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention. Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients. SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model. One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age ≤ 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI ≥ 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn. Patients with SLE onset age ≤ 30, arthritis, existing organ damage (SDI ≥ 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention. BackgroundAvascular necrosis is a common organ damage in SLE patients, which can influence patients’ life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients.MethodsSLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model.ResultsOne hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age ≤ 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI ≥ 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3–6) and low risk (0–2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn.ConclusionPatients with SLE onset age ≤ 30, arthritis, existing organ damage (SDI ≥ 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention. Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients.BACKGROUNDAvascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients.SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model.METHODSSLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model.One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age ≤ 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI ≥ 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn.RESULTSOne hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age ≤ 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI ≥ 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn.Patients with SLE onset age ≤ 30, arthritis, existing organ damage (SDI ≥ 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention.CONCLUSIONPatients with SLE onset age ≤ 30, arthritis, existing organ damage (SDI ≥ 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention. Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients. SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model. One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age [less than or equai to] 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI [greater than or equal to] 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn. |
ArticleNumber | 78 |
Audience | Academic |
Author | Li, Hongbin Cheng, Cheng Huang, Can Li, Mengtao Xu, Jian Wu, Zhenbiao Zhan, Feng Zhao, Cheng Wu, Rui Tian, Xinping Chen, Zhen Yang, Min Zhang, Shangzhu Zeng, Xiaofeng Wang, Qian Duan, Xinwang Wang, Yongfu Zhao, Jiuliang Leng, Xiaomei |
Author_xml | – sequence: 1 givenname: Cheng surname: Cheng fullname: Cheng, Cheng – sequence: 2 givenname: Can surname: Huang fullname: Huang, Can – sequence: 3 givenname: Zhen surname: Chen fullname: Chen, Zhen – sequence: 4 givenname: Feng surname: Zhan fullname: Zhan, Feng – sequence: 5 givenname: Xinwang surname: Duan fullname: Duan, Xinwang – sequence: 6 givenname: Yongfu surname: Wang fullname: Wang, Yongfu – sequence: 7 givenname: Cheng surname: Zhao fullname: Zhao, Cheng – sequence: 8 givenname: Zhenbiao surname: Wu fullname: Wu, Zhenbiao – sequence: 9 givenname: Jian surname: Xu fullname: Xu, Jian – sequence: 10 givenname: Hongbin surname: Li fullname: Li, Hongbin – sequence: 11 givenname: Min surname: Yang fullname: Yang, Min – sequence: 12 givenname: Rui surname: Wu fullname: Wu, Rui – sequence: 13 givenname: Jiuliang surname: Zhao fullname: Zhao, Jiuliang – sequence: 14 givenname: Shangzhu surname: Zhang fullname: Zhang, Shangzhu – sequence: 15 givenname: Qian surname: Wang fullname: Wang, Qian – sequence: 16 givenname: Xiaomei surname: Leng fullname: Leng, Xiaomei – sequence: 17 givenname: Xinping surname: Tian fullname: Tian, Xinping – sequence: 18 givenname: Mengtao surname: Li fullname: Li, Mengtao – sequence: 19 givenname: Xiaofeng surname: Zeng fullname: Zeng, Xiaofeng |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37173771$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kt1q2zAcxc3oWD-2F9jFEOymu3CnT0vezQih6wKBQZpB74Qsy4k620oluSNvtUecnLRbU8bwhcxf5_zEkc5pdtS73mTZWwQvEBLFx4AI5CyHmOSQwALl5EV2gigXeUEKfPTk_zg7DeEWQoxLTF9lx4QjTjhHJ9mvhQ0_QKN0dD6Axnmg7lXQQ6s86I32LtgAbA82KlrTxwB-2rgGYRui6awG7bAZAjB-G9emU9GFIXwCCnRDG22uk8F4oN3a-QhCHOotcA2Yrm1vggHX80uw9EbFLumA6muwSGPl9RpceTdswPn0ejlZfEjjlQ3Rb8HNzWz2OnvZqDaYNw_rWfb9y-Vy-jWff7uaTSfzXLOCxtxwqqDSVFWCo4LwSpuyKRkyTCDYNKZinEOoMGUFqVhdUyhIjbjhuMKUIEzOstmeWzt1KzfedspvpVNW7gbOr6Ty0erWSAEpw4QXouSCUlgLg5GgWtVVQVFtWGJ93rM2Q9WZerwXr9oD6OFOb9dy5e4lgogXJSkT4fyB4N3dYEKUnQ3atK3qjRuCxAIRxkqOx8PeP5PeusH36a5GFSuYwAz-Va1USmD7xqWD9QiVE05LBEu0Y138Q5W-enz91MbGpvmB4d3TpH8iPhYuCcReMFYreNNIbWPqlhuD2zYllmO35b7bMnVb7rotSbLiZ9ZH-n9MvwHFevs8 |
CitedBy_id | crossref_primary_10_3389_fimmu_2024_1288234 crossref_primary_10_3389_fimmu_2024_1381035 crossref_primary_10_1186_s13052_025_01845_8 crossref_primary_10_1016_j_berh_2023_101893 |
Cites_doi | 10.3389/fimmu.2022.1064245 10.1007/s00296-010-1597-9 10.1007/s10067-015-3075-y 10.1136/bmjopen-2020-046163 10.1007/s10753-014-9917-y 10.1007/s11999-010-1292-x 10.1080/08916930400022715 10.1002/art.1780400928 10.1183/13993003.03957-2020 10.1002/art.27236 10.1002/ctm2.526 10.1056/NEJMra071297 10.3389/fmed.2022.847875 10.3109/14397595.2014.987366 10.1093/rheumatology/37.8.895 10.1016/j.semarthrit.2013.05.003 10.1177/0961203306075771 10.2174/1573397117666210907124242 10.1177/09612033211021166 10.1002/acr.24541 10.1177/0961203313500547 10.1016/j.arth.2015.03.036 10.1136/ard.60.12.1145 10.1002/1529-0131(199907)42:7<1405::AID-ANR14>3.0.CO;2-W 10.2478/rir-2021-0001 10.1016/j.autrev.2021.102992 |
ContentType | Journal Article |
Copyright | 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
Copyright_xml | – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
DOI | 10.1186/s13075-023-03061-3 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1478-6362 |
EndPage | 10 |
ExternalDocumentID | oai_doaj_org_article_804523768978440d8e2184cadb641de5 PMC10176939 A749109125 37173771 10_1186_s13075_023_03061_3 |
Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: ; grantid: 2021-I2M-1-005; 2021-I2M-1-005 – fundername: ; grantid: 2021YFC2501300; 2021YFC2501300 – fundername: ; grantid: No.Z201100005520022,23, 25-27; No.Z201100005520022,23, 25-27 – fundername: ; grantid: 2022-PUMCH-B-013, C-002, D-009; 2022-PUMCH-B-013, C-002, D-009 |
GroupedDBID | --- .GJ 0R~ 23N 2WC 4.4 5GY 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABUWG ACGFS ACJQM ADBBV ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK E3Z EBD EBLON EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE HZ~ INH INR ITC KQ8 M1P O5R O5S O9- PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SMD SOJ SV3 TR2 U2A UKHRP WOQ -5E -5G -A0 -BR 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF IAO IHR NPM Z7U PMFND 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c564t-e74a0ac4ab871637bce9f951e5810ffeb57700a24563b5dd4083d17e72b243123 |
IEDL.DBID | 7X7 |
ISSN | 1478-6362 1478-6354 |
IngestDate | Wed Aug 27 01:27:12 EDT 2025 Thu Aug 21 18:37:32 EDT 2025 Fri Jul 11 16:19:29 EDT 2025 Sat Jul 26 00:01:58 EDT 2025 Tue Jun 17 20:59:32 EDT 2025 Tue Jun 10 20:47:05 EDT 2025 Thu Jan 02 22:51:36 EST 2025 Tue Jul 01 04:01:01 EDT 2025 Thu Apr 24 23:07:18 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Avascular necrosis Systemic lupus erythematosus Risk factors Risk stratification |
Language | English |
License | 2023. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c564t-e74a0ac4ab871637bce9f951e5810ffeb57700a24563b5dd4083d17e72b243123 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/2815658250?pq-origsite=%requestingapplication% |
PMID | 37173771 |
PQID | 2815658250 |
PQPubID | 42876 |
PageCount | 10 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_804523768978440d8e2184cadb641de5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10176939 proquest_miscellaneous_2813559725 proquest_journals_2815658250 gale_infotracmisc_A749109125 gale_infotracacademiconefile_A749109125 pubmed_primary_37173771 crossref_citationtrail_10_1186_s13075_023_03061_3 crossref_primary_10_1186_s13075_023_03061_3 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-05-12 |
PublicationDateYYYYMMDD | 2023-05-12 |
PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-12 day: 12 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Arthritis research & therapy |
PublicationTitleAlternate | Arthritis Res Ther |
PublicationYear | 2023 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | MC Hochberg (3061_CR10) 1997; 40 CC Mok (3061_CR24) 1998; 37 A Rahman (3061_CR1) 2008; 358 J Zheng (3061_CR22) 2022; 13 P Migliorini (3061_CR27) 2005; 38 KK Zhu (3061_CR25) 2014; 37 MA Mont (3061_CR15) 2015; 30 J Nakamura (3061_CR18) 2010; 28 K Kaneko (3061_CR17) 2021; 11 V Golder (3061_CR9) 2013; 22 J Nakamura (3061_CR13) 2010; 62 K Oinuma (3061_CR3) 2001; 60 R Prasad (3061_CR20) 2007; 16 Q Wei (3061_CR29) 2021; 11 T Kuroda (3061_CR5) 2015; 34 W Fukushima (3061_CR7) 2010; 468 DD Gladman (3061_CR14) 2001; 28 Y Zheng (3061_CR30) 2022; 21 M Sayarlioglu (3061_CR4) 2012; 32 ST Faezi (3061_CR12) 2015; 25 DD Gladman (3061_CR2) 2000; 27 R Kallas (3061_CR16) 2022; 74 M Li (3061_CR11) 2021; 2 EJ Sutton (3061_CR26) 2013; 43 AA Moghazy (3061_CR19) 2022; 18 CE Evans (3061_CR21) 2021; 58 BC Vande Berg (3061_CR6) 1999; 42 T Nevskaya (3061_CR8) 2017; 35 Y Long (3061_CR23) 2021; 30 J Xiong (3061_CR28) 2022; 9 |
References_xml | – volume: 13 start-page: 1064245 year: 2022 ident: 3061_CR22 publication-title: Front Immunol doi: 10.3389/fimmu.2022.1064245 – volume: 32 start-page: 177 issue: 1 year: 2012 ident: 3061_CR4 publication-title: Rheumatol Int doi: 10.1007/s00296-010-1597-9 – volume: 34 start-page: 2071 issue: 12 year: 2015 ident: 3061_CR5 publication-title: Clin Rheumatol doi: 10.1007/s10067-015-3075-y – volume: 11 start-page: e046163 issue: 7 year: 2021 ident: 3061_CR29 publication-title: BMJ Open doi: 10.1136/bmjopen-2020-046163 – volume: 28 start-page: 761 issue: 4 year: 2001 ident: 3061_CR14 publication-title: J Rheumatol – volume: 37 start-page: 1852 issue: 5 year: 2014 ident: 3061_CR25 publication-title: Inflammation doi: 10.1007/s10753-014-9917-y – volume: 468 start-page: 2715 issue: 10 year: 2010 ident: 3061_CR7 publication-title: Clin Orthop Relat Res doi: 10.1007/s11999-010-1292-x – volume: 38 start-page: 47 issue: 1 year: 2005 ident: 3061_CR27 publication-title: Autoimmunity doi: 10.1080/08916930400022715 – volume: 40 start-page: 1725 issue: 9 year: 1997 ident: 3061_CR10 publication-title: Arthritis Rheum doi: 10.1002/art.1780400928 – volume: 58 start-page: 2003957 issue: 3 year: 2021 ident: 3061_CR21 publication-title: Eur Respir J. doi: 10.1183/13993003.03957-2020 – volume: 62 start-page: 609 issue: 2 year: 2010 ident: 3061_CR13 publication-title: Arthritis Rheum doi: 10.1002/art.27236 – volume: 27 start-page: 373 issue: 2 year: 2000 ident: 3061_CR2 publication-title: J Rheumatol – volume: 11 start-page: e526 issue: 10 year: 2021 ident: 3061_CR17 publication-title: Clin Transl Med doi: 10.1002/ctm2.526 – volume: 35 start-page: 700 issue: 4 year: 2017 ident: 3061_CR8 publication-title: Clin Exp Rheumatol – volume: 358 start-page: 929 issue: 9 year: 2008 ident: 3061_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMra071297 – volume: 9 start-page: 847875 year: 2022 ident: 3061_CR28 publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2022.847875 – volume: 25 start-page: 590 issue: 4 year: 2015 ident: 3061_CR12 publication-title: Mod Rheumatol doi: 10.3109/14397595.2014.987366 – volume: 37 start-page: 895 issue: 8 year: 1998 ident: 3061_CR24 publication-title: Br J Rheumatol doi: 10.1093/rheumatology/37.8.895 – volume: 43 start-page: 352 issue: 3 year: 2013 ident: 3061_CR26 publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2013.05.003 – volume: 16 start-page: 157 issue: 3 year: 2007 ident: 3061_CR20 publication-title: Lupus doi: 10.1177/0961203306075771 – volume: 28 start-page: 13 issue: 1 year: 2010 ident: 3061_CR18 publication-title: Clin Exp Rheumatol – volume: 18 start-page: 144 issue: 2 year: 2022 ident: 3061_CR19 publication-title: Curr Rheumatol Rev doi: 10.2174/1573397117666210907124242 – volume: 30 start-page: 1459 issue: 9 year: 2021 ident: 3061_CR23 publication-title: Lupus doi: 10.1177/09612033211021166 – volume: 74 start-page: 1122 issue: 7 year: 2022 ident: 3061_CR16 publication-title: Arthritis Care Res (Hoboken) doi: 10.1002/acr.24541 – volume: 22 start-page: 1425 issue: 13 year: 2013 ident: 3061_CR9 publication-title: Lupus doi: 10.1177/0961203313500547 – volume: 30 start-page: 1506 issue: 9 year: 2015 ident: 3061_CR15 publication-title: J Arthroplasty doi: 10.1016/j.arth.2015.03.036 – volume: 60 start-page: 1145 issue: 12 year: 2001 ident: 3061_CR3 publication-title: Ann Rheum Dis doi: 10.1136/ard.60.12.1145 – volume: 42 start-page: 1405 issue: 7 year: 1999 ident: 3061_CR6 publication-title: Arthritis Rheum doi: 10.1002/1529-0131(199907)42:7<1405::AID-ANR14>3.0.CO;2-W – volume: 2 start-page: 43 issue: 1 year: 2021 ident: 3061_CR11 publication-title: Rheumatol Immunol Res doi: 10.2478/rir-2021-0001 – volume: 21 start-page: 102992 issue: 2 year: 2022 ident: 3061_CR30 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2021.102992 |
SSID | ssj0022924 |
Score | 2.426808 |
Snippet | Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in... Background Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors... BackgroundAvascular necrosis is a common organ damage in SLE patients, which can influence patients’ life quality. Conflicting results exist in risk factors of... Abstract Background Avascular necrosis is a common organ damage in SLE patients, which can influence patients’ life quality. Conflicting results exist in risk... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 78 |
SubjectTerms | Antibodies Arthritis Arthritis - complications Avascular necrosis Cohort analysis Cohort Studies Complications and side effects Diagnosis Drug dosages East Asian People Glucocorticoids - adverse effects Hematology Humans Lupus Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - epidemiology Magnetic resonance imaging Medical research Necrosis Osteonecrosis - diagnosis Osteonecrosis - epidemiology Osteonecrosis - etiology Patients Pulmonary hypertension Questionnaires Registration Registries Regression analysis Rheumatology Risk Factors Risk stratification Statistical analysis Systemic lupus erythematosus |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gLonwuFDRISIBQ1CS244TbUrVqEeXQbqW9WY7tlIgqW202h_4rfiIzTrLaCAkuXONJZHvG43nx-A1j73JlMqkqG7kstZGQJosK5RJ0hl7I0pbCeLqcfP49O70SX5dyuVPqi3LCenrgfuIOc-L8xlWQI9wRIna5J1BijSszkTgf2EtxzxvB1AC1UoQV4xWZPDts0VMruonMI4qRk4hPtqHA1v-nT97ZlKYJkzs70Mkj9nAIHWHed3mf3fPNY3b_fDgcf8J-XdTtTxgK6AAGo2DGPFNoPPWjbqFuYKBSbYH-wUJP5VxbuOluuxb8-q7ncV21XfsZDISMw4i65NdA5XTXGwictLCqgKpv-9bD5bdjWIwp62AaB2NGH4SfW_Dh6HIxv_iIj69DeTlYLs_OnrKrk-PF0Wk0FGSIrMzEJvJKmNhYYUqCWVyV1hcVhmhe5klcVb6USsWxobNUXkrnBMZ3LlFepWWKgUrKn7G9ZtX4FwxMxRNhq9JWCoMEh6gxFd7RIZ81heTxjCWjfrQd2MqpaMaNDqglz3SvU4061UGnms_Yp-07tz1Xx1-lv5Dat5LEsx0eoPXpwfr0v6xvxt6T0WjyBtg9a4ZLDThI4tXScyUKol5NUfJgIomr2E6bR7PTgxdpdUpUPhIxPE7H220zvUmZcY1fdUGGEyqkTzzvrXQ7JE4pFkolM5ZP7Hcy5mlLU_8IHOPkqbOCFy__xyy9Yg_SsPZklKQHbG-z7vxrjOU25ZuwbH8DHt1EpA priority: 102 providerName: Directory of Open Access Journals |
Title | Risk factors for avascular necrosis in patients with systemic lupus erythematosus: a multi-center cohort study of Chinese SLE Treatment and Research Group (CSTAR) Registry XXII |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37173771 https://www.proquest.com/docview/2815658250 https://www.proquest.com/docview/2813559725 https://pubmed.ncbi.nlm.nih.gov/PMC10176939 https://doaj.org/article/804523768978440d8e2184cadb641de5 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MvY9_z1oUbDLYxTP0hWfZeRlpS2rGWkSaQNyFLchdW7CxOHvZf7U-cTpbTmkFf_GCdjcR96O50-h0h73MuM8YrFeosUSFlMgsLrmNrDA1lpSqpNHg5-fwiO53Tbwu28Am31pdV9jbRGWrdKMyRHyYIa8JsPBN9Xf0OsWsUnq76Fhr3yT5Cl6FU88VNwJUUXVNbaiMlu7HS_tJMnh221nZzvJuchug1x2E62Jgcfv__VvrWNjUsoby1J508Jo-8MwnjjvtPyD1TPyUPzv1x-TPyd7psf4FvqQPWPQXZV55CbXAeyxaWNXhw1RYwKwsduPNSwfV2tW3BrP90yK5Nu22_gARXgxjilMwasMHuegMOpRaaCrAft2kNXH6fwKwvYgdZa-hr_MClu-Dj8eVsPP1kX1-5hnOwWJydPSfzk8ns-DT0LRpCxTK6CQ2nMpKKyhIDr5SXyhSVddoMy-OoqkzJOI8iiaeracm0ptbj0zE3PCkT67ok6QuyVze1eUVAVmlMVVWqilu3Qds4MqFG47GfkgVLo4DEPX-E8vjl2EbjWrg4Js9Ex1NheSocT0UakM-7b1Ydesed1EfI9h0lIm-7F836SnhFFjli0FurnNvwm9JI5waDZCV1mdFYGxaQDyg0Au2DnZ6S_pqDXSQibYkxpwWCsSaW8mBAafVaDYd7sRPerrTiRgsC8m43jF9irVxtmq2jSTFOxF-87KR0t6QUiy44jwOSD-R3sObhSL386VDH0XZnRVq8vnteb8jDxGkVC-PkgOxt1lvz1vptm3LklHNE9o8mFz-mI5f9sM95Mv4HpppC0g |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemIQEviG8KAw4JBAhFy4cdJ0gIlbGpZd0etk7qm3EcZ1RMaWlaof1TiD-ROyfpFiHtbW9R7ES27nx3P_v8O8ZeJ1LHQhbGy-PQeFzo2EtlHqAxtFxkJuPa0uXkg8N4cMK_TcRkg_1p78JQWmVrE52hzmeG9si3Q6I1EYhn_M_zXx5VjaLT1baERq0W-_b8N0K26tPwK8r3TRju7Y53Bl5TVcAzIuZLz0qufW24zggrRDIzNi0wzrAiCfyisJmQ0vc1HQhGmchzjkFKHkgrwyxEb0tEB2jyb-CjT2BPTi4AXpjWRXQ5IjN05Ly9pJPE2xX6Ckl3oSOPovTAizqO0NUL-N8rXHKL3ZTNSz5w7y670wSv0K-17R7bsOV9dvOgOZ5_wP4eTauf0JTwAQyHQbeZrlBaGse0gmkJDZlrBbQLDDWZ9NTA2Wq-qsAuzmsm2Vm1qj6CBpfz6NGQ7AKooO9iCY4VF2YFUP1vW1k4Hu3CuE2aB13m0OYUgtteg3c7x-P-0Xt8feoK3MFkMhw-ZCfXIrxHbLOclfYJA11EATdFZgqJYUqOuDXkNqdjRqNTEfk9FrTyUabhS6eyHWfK4aYkVrVMFcpUOZmqqMc-rL-Z12whV_b-QmJf9ySmb_ditjhVjeFQCXHeoxdIEO5z7ueJJVBudJ7FPMit6LG3pDSK7BEOz-jmWgVOkpi9VF_ylMhfQ-y51emJdsR0m1u1U40dq9TFquuxV-tm-pJy80o7W7k-EeFS-sXjWkvXU4ooyUPKoMeSjv525txtKac_HMs5-Yo4jdKnV4_rJbs1GB-M1Gh4uP-M3Q7dChNeEG6xzeViZZ9jzLjMXriFCuz7dVuGf4PqeyU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+factors+for+avascular+necrosis+in+patients+with+systemic+lupus+erythematosus%3A+a+multi-center+cohort+study+of+Chinese+SLE+Treatment+and+Research+Group+%28CSTAR%29+Registry+XXII&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Cheng%2C+Cheng&rft.au=Huang%2C+Can&rft.au=Chen%2C+Zhen&rft.au=Zhan%2C+Feng&rft.date=2023-05-12&rft.issn=1478-6362&rft.eissn=1478-6362&rft.volume=25&rft.issue=1&rft.spage=78&rft_id=info:doi/10.1186%2Fs13075-023-03061-3&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon |